Comments
Onco Therapies Ltd, a wholly owned subsidiary of Strides Arcolab Ltd, has announced that it has received US FDA approval for its Doxorubicin Hydrochloride injection. Doxorubicin is a cancer chemotherapy drug, used in the treatment of a wide range of cancers, including haematological malignancies, many types of carcinoma, and soft tissue sarcomas. The drug is administered intravenously, in the form of hydrochloride salt. The company in a statement to the exchanges said Doxorubicin is amongst the products in the drug shortage list of US FDA and is part of the oncology portfolio licensed to Pfizer in January 2010. For the US market, the company plans launch shortly in 10 mg/ vial and 50 mg/ vial. According to IMS data in June, the US market for generic Doxorubicin (liquid and lyophilised) is valued around $16.8 million.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.